Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
THE BEST BLACK FRIDAY DEAL YET (Ad)
Best Buy Proves Brick and Mortar is Here to Stay
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
THE BEST BLACK FRIDAY DEAL YET (Ad)
Best Buy Proves Brick and Mortar is Here to Stay
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
THE BEST BLACK FRIDAY DEAL YET (Ad)
Best Buy Proves Brick and Mortar is Here to Stay
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
THE BEST BLACK FRIDAY DEAL YET (Ad)
Best Buy Proves Brick and Mortar is Here to Stay
US-England World Cup game seen by 19.98M on US television
NASDAQ:FUSN

Fusion Pharmaceuticals - FUSN Stock Forecast, Price & News

$2.13
+0.01 (+0.47%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$2.07
$2.20
50-Day Range
$1.98
$3.28
52-Week Range
$1.98
$8.73
Volume
10,300 shs
Average Volume
58,015 shs
Market Capitalization
$95.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Fusion Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
792.0% Upside
$19.00 Price Target
Short Interest
Healthy
0.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.02) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

302nd out of 1,044 stocks

Biological Products, Except Diagnostic Industry

41st out of 174 stocks

FUSN stock logo

About Fusion Pharmaceuticals (NASDAQ:FUSN) Stock

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FUSN Stock News Headlines

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Short Interest Update
See More Headlines
Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FUSN Company Calendar

Last Earnings
11/09/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FUSN
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+792.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-81,050,000.00
Net Margins
-4,189.61%
Pretax Margin
-4,276.81%

Debt

Sales & Book Value

Annual Sales
$1.44 million
Book Value
$5.37 per share

Miscellaneous

Free Float
41,276,000
Market Cap
$95.35 million
Optionable
Not Optionable
Beta
-0.68

Key Executives

  • Dr. John F. Valliant Ph.D. (Age 52)
    Founder, CEO & Director
    Comp: $888.04k
  • Mr. John J. Crowley CPA (Age 48)
    Chief Financial Officer
    Comp: $646.67k
  • Dr. Eric Burak Ph.D. (Age 57)
    Chief Technology Officer
    Comp: $648.31k
  • Mr. Mohit Rawat (Age 42)
    Pres & Chief Bus. Officer
  • Dr. Christopher Paul Leamon Ph.D. (Age 56)
    Chief Scientific Officer
  • Ms. Amanda Cray
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Maria D. Stahl (Age 51)
    Chief Legal Officer
  • Mr. Eric S. Hoffman Ph.D. (Age 52)
    Sr. VP of Bus. Devel.
  • Dr. Cara Ferreira Ph.D.
    Chief of Staff
  • Dr. Victor G. Paulus Ph.D.
    Sr. VP of Regulatory Affairs













FUSN Stock - Frequently Asked Questions

Should I buy or sell Fusion Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FUSN shares.
View FUSN analyst ratings
or view top-rated stocks.

What is Fusion Pharmaceuticals' stock price forecast for 2023?

5 brokerages have issued 12-month target prices for Fusion Pharmaceuticals' stock. Their FUSN share price forecasts range from $19.00 to $19.00. On average, they predict the company's share price to reach $19.00 in the next year. This suggests a possible upside of 789.9% from the stock's current price.
View analysts price targets for FUSN
or view top-rated stocks among Wall Street analysts.

How have FUSN shares performed in 2022?

Fusion Pharmaceuticals' stock was trading at $4.17 on January 1st, 2022. Since then, FUSN shares have decreased by 48.8% and is now trading at $2.1350.
View the best growth stocks for 2022 here
.

When is Fusion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our FUSN earnings forecast
.

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.13. The firm earned $0.33 million during the quarter. Fusion Pharmaceuticals had a negative net margin of 4,189.61% and a negative trailing twelve-month return on equity of 38.72%.

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).

When did Fusion Pharmaceuticals IPO?

(FUSN) raised $126 million in an IPO on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Fusion Pharmaceuticals' stock symbol?

Fusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "FUSN."

Who are Fusion Pharmaceuticals' major shareholders?

Fusion Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (7.09%), RA Capital Management L.P. (1.47%), Point72 Asset Management L.P. (0.69%), Sofinnova Investments Inc. (0.27%), Tekla Capital Management LLC (0.23%) and UBS Group AG (0.13%). Insiders that own company stock include Adams Street Partners Llc, John Valliant, Johnson & Johnson and Steven Gannon.
View institutional ownership trends
.

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fusion Pharmaceuticals' stock price today?

One share of FUSN stock can currently be purchased for approximately $2.14.

How much money does Fusion Pharmaceuticals make?

Fusion Pharmaceuticals (NASDAQ:FUSN) has a market capitalization of $95.56 million and generates $1.44 million in revenue each year. The company earns $-81,050,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

How can I contact Fusion Pharmaceuticals?

Fusion Pharmaceuticals' mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The official website for the company is fusionpharma.com. The company can be reached via phone at 289-799-0891 or via email at ir@fusionpharma.com.

This page (NASDAQ:FUSN) was last updated on 11/28/2022 by MarketBeat.com Staff